Стойкий эффект тоцилизумаба при рефрактерном артериите Такаясу (клиническое наблюдение)

Изучение роли интерлейкина 6 (ИЛ-6) в развитии хронического аутоиммунного воспаления привело к разработке инновационных методов лечения различных иммуновоспалительных ревматических заболеваний, в том числе артериита Такаясу (АТ). Учитывая важную роль ИЛ-6 в патогенезе АТ и его связь с высокой клинико-лабораторной активностью заболевания, тоцилизумаб (ТЦЗ) рекомендован в качестве препарата второй линии в случае неэффективности как глюкокортикоидов и базисных противовоспалительных препаратов, так и предшествующей терапии ингибиторами фактора некроза опухоли α. В статье представлено собственное наблюдение успешного применения ТЦЗ у пациентки с АТ рефрактерного течения.

1. Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65(1):1-11. doi: 10.1002/art.37715. PMID: 23045170

2. Johnston SL, Lock RJ, Gompels MM. Takayasu arteritis: A review. J Clin Pathol. 2002;55(7):481-486. doi: 10.1136/jcp.55.7.481

3. Watts R, Al-Taiar A, Mooney J, Scott D, Macgregor A. The epidemiology of Takayasu arteritis in the UK. Rheumatology (Oxford). 2009;48(8):1008-1011. doi: 10.1093/rheumatology/kep153

4. Hall S, Barr W, Lie JT, Stanson AW, Kazmier FJ, Hunder GG. Takayasu arteritis. A study of 32 North American patients. Medicine (Baltimore). 1985;64(2):89-99.

5. Kerr GS, Hallahan CW, Giordano J, Leavitt RY, Fauci AS, Rottem M, et al. Takayasu arteritis. Ann Intern Med. 1994;120(11): 919-929. doi: 10.7326/0003-4819-120-11-199406010-00004

6. Bicakcigil M, Aksu K, Kamali S, Ozbalkan Z, Ates A, Karadag O, et al. Takayasu’s arteritis in Turkey – Clinical and angiographic features of 248 patients. Clin Exp Rheumatol. 2009;27(1 Suppl 52): S59-S64.

7. Karageorgaki ZT, Bertsias GK, Mavragani CP, Kritikos HD, Spyropoulou-Vlachou M, Drosos AA, et al. Takayasu arteritis: Epidemiological, clinical, and immunogenetic features in Greece. Clin Exp Rheumatol. 2009;27(1 Suppl 52): S33-S39.

8. Moriwaki R, Noda M, Yajima M, Sharma BK, Numano F. Clinical manifestations of Takayasu arteritis in India and Japan – New classification of angiographic findings. Angiology. 1997;48(5):369-379. doi: 10.1177/000331979704800501

9. Watanabe Y, Miyata T, Tanemoto K. Current clinical features of new patients with Takayasu arteritis observed from cross-country research in Japan: Age and sex specificity. Circulation. 2015;132:17019. doi: 10.1161/CIRCULATIONAHA.114.012547

10. Brunner J, Feldman BM, Tyrrell PN, Kuemmerle-Deschner JB, Zimmerhackl LB, Gassner I, et al. Takayasu arteritis in children and adolescents. Rheumatology (Oxford). 2010;49(10):1806-1814. doi: 10.1093/rheumatology/keq167

11. Noris M, Daina E, Gamba S, Bonazzola S, Remuzzi G. Interleukin-6 and RANTES in Takayasu arteritis: A guide for therapeutic decisions? Circulation. 1999;100(1):55-60. doi: 10.1161/01.cir.100.1.55

12. Park MC, Lee SW, Park YB, Lee SK. Serum cytokine profiles and their correlations with disease activity in Takayasu’s arteritis. Rheumatology (Oxford). 2006;45(5):545-548. doi: 10.1093/rheumatology/kei266

13. Alibaz-Oner F, Yentür SP, Saruhan-Direskeneli G, Direskeneli H. Serum cytokine profiles in Takayasu’s arteritis: Search for biomarkers. Clin Exp Rheumatol. 2015;33(2 Suppl 89): S32-S35.

14. Saadoun D, Garrido M, Comarmond C, Desbois AC, Domont F, Savey L, et al. Th1 and Th17 cytokines drive inflammation in Takayasu arteritis. Arthritis Rheumatol. 2015;67(5):1353-1360. doi: 10.1002/art.39037

15. Kong X, Sun Y, Ma L, Chen H, Wei L, Wu W, et al. The critical role of IL-6 in the pathogenesis of Takayasu arteritis. Clin Exp Rheumatol. 2016;34(3 Suppl 97): S21-S27.

16. Насонов ЕЛ, Лила АМ. Ингибиция интерлейкина 6 при иммуновоспалительных ревматических заболеваниях: достижения, перспективы и надежды. Научно-практическая ревматология. 2017;55(6):590-599. doi: 10.14412/1995-4484-2017-590-599

17. Насонов ЕЛ, Лила АМ, Чой Э. Второе поколение ингибиторов рецепторов интерлейкина 6 – новая веха в ревматологии. Эффективная фармакотерапия. 2019;15(23). URL: https://umedp.ru/articles/vtoroe_pokolenie_ingibitorov_retseptorov_interleykina_6_novaya_vekha_v_revmatologii_obshcherossiyski.html (Дата доступа: ##.##.2022)

18. Nishimoto N, Nakahara H, Yoshio-Hoshino N, Mima T. Successful treatment of a patient with Takayasu arteritis using a humanized anti-interleukin-6 receptor antibody. Arthritis Rheum. 2008;58(4):1197-1200. doi: 10.1002/art.23373. PMID: 18383395

19. Nakaoka Y, Isobe M, Takei S, Tanaka Y, Ishii T, Yokota S, et al. Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: Results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study). Ann Rheum Dis. 2018;77(3):348-354. doi: 10.1136/annrheumdis-2017-211878

20. Koster MJ, Matteson EL, Warrington KJ. Recent advances in the clinical management of giant cell arteritis and Takayasu arteritis. Curr Opin Rheumat, 2016;28:211-217. doi: 10.1097/BOR.0000000000000265

21. Hoffman GS, Leavitt RY, Kerr GS, Rottem M, Sneller MC, Fauci AS. Treatment of glucocorticoid-resistant or relapsing Takayasu arteritis with methotrexate. Arthritis Rheum. 1994;37(4):578-582. doi: 10.1002/art.1780370420

22. Valsakumar AK, Valappil UC, Jorapur V, Garg N, Nityanand S, Sinha N. Role of immunosuppressive therapy on clinical, immunological, and angiographic outcome in active Takayasuэs arteritis. J Rheumatol. 2003;30(8):1793-1798.

23. Shinjo SK, Pereira RM, Tizziani VA, Radu AS, Levy-Neto M. Mycophenolate mofetil reduces disease activity and steroid dosage in Takayasu arteritis. Clin Rheumatol. 2007;26(11):1871-1875. doi: 10.1007/s10067-007-0596-z

24. Nakaoka Y, Higuchi K, Arita Y, Otsuki M, Yamamoto K, Hashimoto-Kataoka T, et al. Tocilizumab for the treatment of patients with refractory Takayasu arteritis. Int Heart J. 2013;54(6):405-411. doi: 10.1536/ihj.54.405

25. Mekinian A, Néel A, Sibilia J, Cohen P, Connault J, Lambert M, et al.; Club Rhumatismes et Inflammation, French Vasculitis Study Group and Société Nationale Française de Médecine Interne. Efficacy and tolerance of infliximab in refractory Takayasu arteritis: French multicentre study. Rheumatology (Oxford). 2012;51(5):882-886. doi: 10.1093/rheumatology/ker380

26. Clifford A, Clifford A, Hoffman GS. Recent advances in the medical management of Takayasu arteritis: An update on use of biologic therapies. Curr Opin Rheumatol. 2014;26:7-15.doi: 10.1097/BOR.0000000000000004

27. Mekinian A, Comarmond C, Resche-Rigon M, Mirault T, Kahn JE, et al.; French Takayasu Network. Efficacy of biologicaltargeted treatments in Takayasu arteritis: Multicenter, retrospective study of 49 patients. Circulation. 2015;132(18):1693-1700. doi: 10.1161/CIRCULATIONAHA.114.014321

28. Schmidt J, Kermani TA, Bacani AK, Crowson CS, Matteson EL, Warrington KJ. Tumor necrosis factor inhibitors in patients with Takayasu arteritis: Experience from a referral center with long-term followup. Arthritis Care Res (Hoboken). 2012;64(7):1079-1083. doi: 10.1002/acr.21636

29. Hellmich B, Agueda A, Monti S, Buttgereit F, de Boysson H, Brouwer E, et al. 2018 Update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis. 2020;79(1):19-30. doi: 10.1136/annrheumdis-2019-215672

30. Arend WP, Michel BA, Bloch DA, Hunder GG, Calabrese LH, Edworthy SM, et al. The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum. 1990;33(8):1129-1134. doi: 10.1002/art.1780330811

31. Sharma BK, Jain S, Suri S, Numano F. Diagnostic criteria for Takayasu arteritis. Int J Cardiol. 1996;54(Suppl): S141-S147. doi: 10.1016/s0167-5273(96)88783-3

32. Luqmani R. Evaluation of vasculitis disease activity in Europe. Eur J Intern Med. 2001;12(5):401-402. doi: 10.1016/s09536205(01)00158-3

33. Maksimowicz-McKinnon K, Clark T, Hoffman G. Limitations of therapy and a guarded prognosis in an American cohort of Takayasu arteritis patients. Arthritis Rheum, 2007;56(3):10001009. doi: 10.1002/art.22404

34. Isobe M. Takayasu arteritis revisited: current diagnosis and treatment. Int J Cardiol. 2013;168:3-10. doi: 10.1016/j.ijcard.2013.01.022

35. Abisror N, Mekinian A, Lavigne C, Vandenhende MA, Soussan M, Fain O; Club Rhumatismes et Inflammation, and SNFMI. Tocilizumab in refractory Takayasu arteritis: A case series and updated literature review. Autoimmun Rev. 2013;12(12):11431149. doi: 10.1016/j.autrev.2013.06.019

36. Unizony S, Arias-Urdaneta L, Miloslavsky E, Arvikar S, Khosroshahi A, Keroack B, et al. Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica. Arthritis Care Res (Hoboken). 2012;64(11):1720-1729. doi: 10.1002/acr.21750

37. Salvarani C, Magnani L, Catanoso M, Pipitone N, Versari A, Dardani L, et al. Tocilizumab: A novel therapy for patients with large-vessel vasculitis. Rheumatology (Oxford). 2012;51(1):151-156. doi: 10.1093/rheumatology/ker296

38. Cañas CA, Cañas F, Izquierdo JH, Echeverri AF, Mejía M, Bonilla-Abadía F, et al. Efficacy and safety of anti-interleukin 6 receptor monoclonal antibody (tocilizumab) in Colombian patients with Takayasu arteritis. J Clin Rheumatol. 2014;20(3): 125-129. doi: 10.1097/RHU.0000000000000098

39. Бекетова ТВ, Насонов ЕЛ. Инновационные методы лечения артериита Такаясу: в фокусе ингибиторы интерлейкина 6. Собственный опыт применения тоцилизумаба и обзор литературы. Научно-практическая ревматология. 2017;55(5):536548. doi: 10.14412/19954484-2017-536-548